The company also updated investors on its ELEVIDYS gene therapy label, agreed to an FDA-requested black box warning, and outlined plans to resume dosing in non-ambulant patients.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Palantir co-founder Joe Lonsdale is calling for a tech-led overhaul of the FDA through a "special forces" AI team to accelerate drug approvals, warning that outdated systems are allowing China to surpass the U.S. in biotech innovation.
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
